Intellia announces positive long-term data from its ongoing Phase 1 study of NTLA-2002 for #hereditaryangioedema at @EAACI_HQ 2024 Congress. Full details here: https://lnkd.in/evkqTURF #HAE #CRISPR #geneediting
Intellia Therapeutics, Inc.
Biotechnology Research
Cambridge, Massachusetts 53,945 followers
Developing curative genome editing treatments
About us
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .
- Website
-
http://www.intelliatx.com
External link for Intellia Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2014
Locations
-
Primary
Get directions
40 Erie Street
Cambridge, Massachusetts 02139, US
Employees at Intellia Therapeutics, Inc.
Updates
-
In chapter three of our series, we learn Shanna’s twins inherited not only hereditary angioedema (#HAE) and its associated challenges, but also their parents’ incredible resiliency. Despite feeling the weight of this disease, the family faces it together — through good days and bad. #GenomeJourney
-
Don't miss our Chief Medical Officer, David Lebwohl, M.D., speak on "Accelerated Approvals: The Viability of Surrogate Endpoints" at the ISCT, International Society for Cell & Gene Therapy Conference in Vancouver, Canada, on May 31 at 9:15 a.m. Details here: https://lnkd.in/e7u6YWzk #ISCT2024
-
Meet Vinita, a scientist in Nucleic Acid Therapeutics and Development. She has prioritized her growth and professional development over the past six years working at Intellia. Follow #IntelliaCareerJourneys to keep up with our latest stories!
-
#MemorialDay is a time to remember and honor the sacrifices made by our brave soldiers. As we celebrate with family and friends, let's not forget to pay tribute to those who gave their lives for our freedom.
-
-
The Intellia team is looking forward to attending The International Society Of Amyloidosis Symposium in Rochester, MN, this week. To learn more about Intellia and #CRISPR #geneediting, stop by our exhibit booth or catch one of our May 29th poster presentations. More here: https://lnkd.in/ej-E4aQf #ISA2024
-
-
In the second chapter of their story, Shanna describes the symptoms of hereditary angioedema (#HAE) and the reality of living with this #raredisease. Learn more about their experience and the challenges they face. #GenomeJourney
-
This week on “Imagine the Possibilities with Intellia,” we spoke with Stephanie, executive director, Medical Governance and Strategic Capabilities, about her journey to Intellia and the valuable work happening in Medical Affairs. Stream on your favorite podcast platform today! #OneIntellia
-
At Intellia, we see #HAEDay as an opportunity to reaffirm our commitment to not only advancing treatment, but also fostering a vibrant community of support. Let's use #HAEDay to come together and spread awareness. #OneIntellia
-
In honor of #HAE Day, we are sharing Shanna’s story with hereditary angioedema to help you learn more about this #raredisease. For people living with HAE, awareness is key to receiving the right diagnosis and treatment plan. Shanna’s diagnosis took four years, a period that included confusion, uncertainty and, ultimately, realization of the gravity of this condition. More than 15,000 people in the U.S. and Europe are affected by HAE. Learn about Shanna’s journey, and find out more about HAE through our #GenomeJourney video series: https://bit.ly/3ROZkP4 #active4HAE